搜索医生

Mahesh Seetharam, M.D.

  1. Hematologist
  2. Oncologist
预约门诊

出版物

  1. Ailts I, Golafshar MA, Kunze KL, Klint M, Barrus K, Nussbaum RL, Esplin ED, Leach B, Young S, Samadder NJ, Seetharam M. Germline Genetic Testing in Patients with Bone and Soft Tissue Sarcoma: A Prospective Multicenter Study to Evaluate Cancer Susceptibility. Int J Mol Sci. 2025 Mar 21; 26 (7)
    View PubMed
  2. Papke DJ Jr, Chrisinger JSA, French CA, Crymes A, Krivak TC, Estape RE, Seetharam M, Patel RA, O'Connor WN, Chi AW, Gutman P, Singer S, Kim C, Bryant DA, Oberley MJ, Adeyelu T, Bridge JA, Evans MG. MAD::NUT Fusion Sarcoma: A Sarcoma Class With NUTM1, NUTM2A, and NUTM2G Fusions and Possibly Distinctive Subtypes. Mod Pathol. 2025 Feb 6; 38 (5):100729 Epub 2025 Feb 06
    View PubMed
  3. Norman A, Seetharam M, Allred J, Kong J, Opyrchal M, Ma WW, Lou Y, Dy GK, Mahipal A, Weroha SJ, Wahner Hendrickson AE, Reid JM, Adjei AA. A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors. BJC Rep. 2025 Jan 14; 3 (1):1
    View PubMed
  4. Stoff R, Markovic SN, McWilliams RR, Kottschade LA, Montane HN, Dimou A, Dudek AZ, Tan W, Dronca RS, Seetharam M, Chen R, Block MS. Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting. Melanoma Res. 2024 Dec 1; 34 (6):510-518 Epub 2024 Aug 30
    View PubMed
  5. Cote GM, Conley AP, Attia S, Van Tine BA, Seetharam M, Chen YL, Gafoor Z, Heery C, Pico-Navarro C, Adams T. A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma. Cancer. 2024 Nov 15; 130 (22):3845-3854 Epub 2024 July 10
    View PubMed
  6. Karigyo CJT, Pessoa BMS, Nicacio SP, Terwilliger E, Costa P, Santos PRD, Ernani V, Seetharam M, Murakami AN, Batalini F. Cardiac Tumors: Review. Braz J Cardiovasc Surg. 2024 Jul 22; 39 (6):e20230405 Epub 2024 July 22
    View PubMed
  7. Emiloju OE, Yin J, Koubek E, Reid JM, Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA, Davis SL, Gores GJ, Roberts LR, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. Invest New Drugs. 2024 Feb; 42(1):127-135. Epub 2024 Jan 25.
    View PubMed
  8. Li Y, Huang J, Chen X, Ye Y, Du X, Voutsadakis IA, Seetharam M, Zhang H, Lu M. Case report: Metastatic refractory undifferentiated small round-cell sarcoma successfully treated with surufatinib and camrelizumab. Front Oncol. 2024; 14:1416241 Epub 2024 July 11
    View PubMed
  9. Ingham M, Allred JB, Chen L, Das B, Kochupurakkal B, Gano K, George S, Attia S, Burgess MA, Seetharam M, Boikos SA, Bui N, Chen JL, Close JL, Cote GM, Thaker PH, Ivy SP, Bose S, D'Andrea A, Marino-Enriquez A, Shapiro GI, Schwartz GK. Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). J Clin Oncol. 2023 Sep 1; 41 (25):4154-4163 Epub 2023 July 19
    View PubMed
  10. Huff D, Horsley RK, Seetharam M, Larsen BT. Undifferentiated Pleomorphic Sarcoma Presenting as Hip Pain. Am J Med. 2023 Sep; 136 (9):e171-e172 Epub 2023 May 04
    View PubMed
  11. Watters CR, Barro O, Elliott NM, Zhou Y, Gabere M, Raupach E, Baker AT, Barrett MT, Buetow KH, Jacobs B, Seetharam M, Borad MJ, Nagalo BM. Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma. Mol Ther Oncolytics. 2023 Jun 15; 29:4-14. Epub 2023 Mar 01.
    View PubMed
  12. Heater NK, Okuno S, Robinson S, Attia S, Seetharam M, Siontis BL, Yoon J, Chawla S, Milhem MM, Monga V, Skubitz K, Charlson J, Hirbe AC, Weiss MC, Van Tine B, Agulnik M. The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma. J Clin Med. 2023 Mar 29; 12 (7)
    View PubMed
  13. Haug LP, Zarka MA, D'Cunha J, Downey FX 3rd, Seetharam M, Yang M. Pulmonary Artery Angiomatoid Fibrous Histiocytoma Mimicking a Large Pulmonary Embolism. Clin Nucl Med. 2022 Dec 1; 47 (12):e738-e739 Epub 2022 June 11
    View PubMed
  14. Laughlin BS, Golafshar MA, Lin K, Goulding K, Roesler K, Vern-Gross T, Seetharam M, Zaniletti I, Ashman JB. Long-term experience with intraoperative electron radiation therapy boost in extremity sarcoma. J Surg Oncol. 2022 Dec; 126 (7):1279-1287 Epub 2022 July 20
    View PubMed
  15. Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, Nadal E, Vuky J, Lopes G, Kalemkerian GP, Bowles DW, Seetharam M, Chang J, Zhang H, Green J, Zalutskaya A, Schuler M, Fan Y, Curigliano G. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022 Aug; 28 (8):1640-1645 Epub 2022 Aug 12
    View PubMed
  16. Laughlin BS, Golafshar MA, Ahmed S, Prince M, Anderson JD, Vern-Gross T, Seetharam M, Goulding K, Petersen I, DeWees T, Ashman JB. Early Experience Using Proton Beam Therapy for Extremity Soft Tissue Sarcoma: A Multicenter Study. Int J Part Ther. 2022 Summer; 9(1):1-11. Epub 2022 May 06.
  17. Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen RB, Lou Y, Hauke R, Vogelzang N, P Zandberg D, Kalebasty AR, Atkinson V, Adjei AA, Seetharam M, Birnbaum A, Weickhardt A, Ganju V, Joshua AM, Cavallo R, Peng L, Zhang X, Kaul S, Baughman J, Bonvini E, Moore PA, Goldberg SM, Arnaldez FI, Ferris RL, Lakhani NJ. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. J Immunother Cancer. 2022 Apr; 10 (4)
    View PubMed
  18. Zurcher KS, Houghton OM, Shen JF, Seetharam M, Roarke MC, Yang M. Nuclear Medicine and Molecular Imaging in Nodal Staging and Surveillance of Ocular Melanoma: Case Reports and Review of the Literature. J Nucl Med Technol. 2021 Sep; 49 (3):275-280 Epub 2021 Apr 05
    View PubMed
  19. Chawla N, Bui NQ, Seetharam M. Evolving role of entrectinib in treatment of NTRK-positive tumors. Future Oncol. 2021 Aug; 17 (22):2835-2846 Epub 2021 Apr 26
    View PubMed
  20. Brumfiel CM, Patel MH, Aqel B, Lehrer M, Patel SH, Seetharam M. Immune checkpoint inhibitor therapy in a liver transplant recipient with autoimmune disease and metastatic cutaneous squamous cell carcinoma. JAAD Case Rep. 2021 Aug; 14:78-81 Epub 2021 June 04
    View PubMed
  21. Hirbe AC, Eulo V, Moon CI, Luo J, Myles S, Seetharam M, Toeniskoetter J, Kershner T, Haarberg S, Agulnik M, Monga V, Milhem M, Parkes A, Robinson S, Okuno S, Attia S, Van Tine BA. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. Eur J Cancer. 2020 Sep; 137:1-9 Epub 2020 July 23
    View PubMed
  22. Monga V, Skubitz KM, Maliske S, Mott SL, Dietz H, Hirbe AC, Van Tine BA, Oppelt P, Okuno S, Robinson S, O'Connor M, Seetharam M, Attia S, Charlson J, Agulnik M, Milhem M. A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas. Cancers (Basel). 2020 Jul 11; 12 (7) Epub 2020 July 11
    View PubMed
  23. Pollack SM, Somaiah N, Araujo DM, Druta M, Van Tine BA, Burgess MA, Chawla SP, Seetharam M, Okuno SH, Bohac C, Chen M, Yurasov S, Attia S. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med. 2020 Jul; 9 (13):4593-4602 Epub 2020 May 06
    View PubMed
  24. DeLeon TT, Almquist DR, Kipp BR, Langlais BT, Mangold A, Winters JL, Kosiorek HE, Joseph RW, Dronca RS, Block MS, McWilliams RR, Kottschade LA, Rumilla KM, Voss JS, Seetharam M, Sekulic A, Markovic SN, Bryce AH. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. PLoS One. 2020; 15 (3):e0230306 Epub 2020 Mar 20
    View PubMed
  25. Cheng TW, Yu NY, Seetharam M, Patel SH. Radiotherapy for malignant melanoma of the lacrimal sac. Rare Tumors. 2020; 12:2036361320971943 Epub 2020 Nov 11
    View PubMed
  26. Nguyen BD, Seetharam M, Ocal TI. 18F-FDG PET/CT Imaging of Trichoblastic Carcinoma With Nodal Metastasis. Clin Nucl Med. 2019 Jul; 44 (7):e423-e424
    View PubMed
  27. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH, CASSINI Investigators, Seetharam M. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019 Feb 21; 380 (8):720-728
    View PubMed
  28. Meyer M, Seetharam M. First-Line Therapy for Metastatic Soft Tissue Sarcoma. Curr Treat Options Oncol. 2019 Jan 24; 20 (1):6
    View PubMed
  29. Seetharam M, Kolla KR, Ganjoo KN. Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma. Future Oncol. 2018 Oct; 14 (23):2323-2333 Epub 2018 June 05
    View PubMed
  30. Seetharam M, Kolla KR, Chawla SP. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma. Future Oncol. 2018 Jul; 14 (16):1531-1545 Epub 2018 Feb 07
    View PubMed
  31. Seetharam M, Kolla KR, Chawla S. Immunotherapy for Sarcomas - The Past, Present and Future. J Oncol Res Ther. 2018; JONT-157.
  32. Seetharam M, Kolla KR, Chawla SP. Metastatic Soft Tissue Sarcomas: A Review of Treatments and New Pharmacotherapies. Clin Oncol. 2018; 3:1426.
  33. Richards D, Li SG, Anderson T, Seetharam M, et al. Tumor and host characteristics of small cell lung cancer (SCLC) in U.S. community oncology practice. J Immunotherapy Cancer.2017;3(Suppl 2)P170.
  34. Malla M, Seetharam M. To treat or not to treat: a rare case of pseudo-thrombotic thrombocytopenic purpura in a Jehovah's Witness. Transfusion. 2016 Jan; 56: (1)160-3.
    View PubMed
  35. Weinberg OK, Seetharam M, Ren L, Alizadeh A, Arber DA. Mixed phenotype acute leukemia: A study of 61 cases using World Health Organization and European Group for the Immunological Classification of Leukaemias criteria. Am J Clin Pathol. 2014 Dec; 142: (6)803-8.
    View PubMed
  36. Weinberg OK, Ohgami RS, Ma L, Seo K, Ren L, Gotlib JR, Seetharam M, Cherry A, Arber DA. Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings. Am J Clin Pathol. 2014 Aug; 142: (2)190-5.
    View PubMed
  37. Ohgami RS, Ma L, Ren L, Weinberg OK, Seetharam M, Gotlib JR, Arber DA. DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups. Br J Haematol. 2012 Oct; 159: (2)182-90.
    View PubMed
  38. Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res. 2012 Jan; 36: (1)98-103.
    View PubMed
  39. Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker JD, Gotlib J, Zehnder JL, Arber DA. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009 Feb 26; 113: (9)1906-8.
    View PubMed
  40. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol. 2007 Oct; 178: (4 Pt 1)1515-20.
    View PubMed
  41. Isufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, Pahanish P, Verma A. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res. 2007 Jul; 27: (7)543-52.
    View PubMed
PST-20308504